Abliva AB (FRA:NTP) Cash-to-Debt : 211.00 (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Abliva AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Abliva AB's cash to debt ratio for the quarter that ended in Jun. 2024 was 211.00.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Abliva AB could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Abliva AB's Cash-to-Debt or its related term are showing as below:

FRA:NTP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.99 Med: No Debt Max: No Debt
Current: 209.51

During the past 13 years, Abliva AB's highest Cash to Debt Ratio was No Debt. The lowest was 0.99. And the median was No Debt.

FRA:NTP's Cash-to-Debt is ranked better than
83.07% of 1494 companies
in the Biotechnology industry
Industry Median: 6.255 vs FRA:NTP: 209.51

Abliva AB Cash-to-Debt Historical Data

The historical data trend for Abliva AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Abliva AB Cash-to-Debt Chart

Abliva AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

163.68

673.22

No Debt

123.25

135.66

Abliva AB Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Cash-to-Debt	Get a 7-Day Free Trial															103.13	112.66	135.66	98.32	211.00

Competitive Comparison of Abliva AB's Cash-to-Debt

For the Biotechnology subindustry, Abliva AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abliva AB's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abliva AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Abliva AB's Cash-to-Debt falls into.

Abliva AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Abliva AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.155	/	(0	+	0.038)
	=	135.66

Abliva AB's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.009	/	(0	+	0.019)
	=	211.00

Abliva AB (FRA:NTP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Abliva AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Abliva AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Abliva AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (FRA:NTP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

NEVPF:USA ABLI:Sweden 0QDU:UK NTP:Germany

Address

Scheeletorget 1, Medicon Village, Lund, SWE, 223 81

Website

https://www.abliva.com

Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.

Abliva AB Headlines

No Headlines